[Transfusion independence achieved with pomalidomide therapy in a patient with primary myelofibrosis].

Abstract

Primary myelofibrosis (PMF) is commonly associated with anemia. IMiD® immunomodulatory drugs including thalidomide and lenalidomide have been shown to be effective in improving anemia associated with PMF. However, because of adverse events, their use has been restricted. Herein we report the case of a 67-year-old male patient with transfusion-dependent PMF treated with the immunomodulatory drug pomalidomide in a clinical trial. Significant improvements in anemia and thrombocytopenia were observed with pomalidomide, and the patient recovered from transfusion dependence for 8 months. Although phase 3 trial failed to show the superiority of pomalidomide over placebo, pomalidomide may have some benefit in selected patients with transfusion-dependent PMF.

• Authors: Yoko Edahiro, Akihiko Gotoh, Tadaaki Inano, Miyuki Tsutsui, Yutaka Tsukune, Hajime Yasuda, Norio Komatsu
• Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology (Rinsho Ketsueki) 2018 Vol. 59 Issue 3 Pg. 323-325 ISSN: 0485-1439 [Print] Japan
• PMID: 29618692 (Publication Type: Case Reports, Journal Article)

Chemical References

• Thalidomide
• pomalidomide

Topics

• Aged
• Anemia (complications, drug therapy)
• Blood Transfusion
• Humans
• Male
• Primary Myelofibrosis (complications, drug therapy)
• Thalidomide (analogs & derivatives, therapeutic use)